New data hub will accelerate development and adoption of human-based New Approach Methodologies The NYU Langone-Sage ...
A research team at NYU Langone Health and Sage Bionetworks has been awarded a $25 million grant to establish the data hub and coordinating center for the National Institutes of Health's ...
In the spring of 2020, the Federal Reserve faced a challenge: The COVID-19 pandemic was upending daily life with shutdowns, social distancing, and heightened uncertainty, but the traditional economic ...
Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study140.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1Fabhalta ...
A research team at NYU Langone Health and Sage Bionetworks has been awarded a $25 million grant to establish the ...
Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study140.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1Fabhalta gr ...
Weather derivatives, particularly Rainfall Index contracts, can complement crop insurance by offering faster, transparent ...
Ocugen (NASDAQ:OCGN) presented top-line 12-month results from its Phase II ArMaDa clinical trial evaluating OCU410, a ...
Clinical trial datasets are becoming increasingly complex, yet the format of their dissemination remains largely static.1 ...
Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at ...
Good morning, and welcome to Ocugen's Webcast to discuss the Top Line 12-month Results from Phase II ArMaDa Clinical Trial Evaluating OCU410 for Geographic Atrophy or GA Secondary to Dry Age-related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results